Related Experiment Video
Updated: Jun 13, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Lipoprotein(a) and cardiovascular disease
Børge G Nordestgaard1, Anne Langsted1
1Department of Clinical Biochemistry, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
High lipoprotein(a) increases cardiovascular risk. Lifetime measurement of lipoprotein(a) can guide lifestyle and medication for high-risk individuals, with promising new drugs in development.
Area of Science:
- Cardiology
- Genetics
- Epidemiology
Background:
- High lipoprotein(a) affects 1 in 5 people, increasing risk for atherosclerotic cardiovascular disease and aortic valve stenosis.
- Lipoprotein(a) levels exhibit significant ethnic and sex-based variations, with concentrations being genetically determined.
- Current management focuses on lifestyle and other risk factor reduction due to lack of approved therapies targeting lipoprotein(a).
Purpose of the Study:
- To provide a comprehensive review of lipoprotein(a) in cardiovascular disease.
- To discuss the genetic, epidemiological, and clinical aspects of lipoprotein(a).
- To explore current and future therapeutic strategies for lowering lipoprotein(a).
Main Methods:
- Review of historical perspectives, physiology, pathophysiology, and genetic evidence.
- Analysis of epidemiological data on lipoprotein(a) concentrations across diverse populations.
- Examination of the role of lipoprotein(a) in familial hypercholesterolemia and diabetes.
- Assessment of current management, screening, diagnosis, and prevention strategies.
- Evaluation of emerging lipoprotein(a)-lowering drugs in clinical trials.
Main Results:
- Lipoprotein(a) concentrations are lowest in East/Southeast Asians and Europeans, intermediate in South Asians/Middle Easterners/Latin Americans, and highest in Africans.
- Concentrations are over 90% genetically determined and 17% higher in post-menopausal women than men.
- Numerous drugs in development show potential to significantly lower lipoprotein(a) by 65-98%.
Conclusions:
- Lifetime screening of lipoprotein(a) is recommended for individuals at high cardiovascular risk.
- Early detection and risk factor management are crucial for individuals with elevated lipoprotein(a).
- Emerging therapies hold significant promise for directly reducing lipoprotein(a) and mitigating cardiovascular risk.
Related Concept Videos
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipids: Dietary Sources and Requirements
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

